Detalles de la búsqueda
1.
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
BMC Health Serv Res
; 21(1): 255, 2021 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743684
2.
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Cult Health Sex
; 23(8): 1066-1078, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32436478
3.
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
AIDS Behav
; 24(12): 3473-3481, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32410051
4.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32447500
5.
Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
BMC Womens Health
; 20(1): 152, 2020 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32711509
6.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28750935
7.
Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
Ann Pharmacother
; 50(12): 989-1000, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27439947
8.
Annual direct medical cost of active systemic lupus erythematosus in five European countries.
Ann Rheum Dis
; 73(1): 154-60, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23264339
9.
Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
Eur J Rheumatol
; 10(1): 39-44, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880810
10.
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
Patient
; 15(1): 131-143, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34180035
11.
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial.
AIDS Res Hum Retroviruses
; 37(3): 207-213, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33323029
12.
Comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006-2007.
Clin Infect Dis
; 51(8): 925-8, 2010 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20815734
13.
Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial.
HIV Res Clin Pract
; 21(4): 105-113, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33048662
14.
"It made me more confident that I have it under control": Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain.
PLoS One
; 15(5): e0232473, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32357195
15.
"A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania.
PLoS One
; 15(6): e0234666, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32530939
16.
Voluntary and mandatory surveillance for methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) bacteraemia in England.
J Antimicrob Chemother
; 64 Suppl 1: i11-7, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19675013
17.
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
HIV Res Clin Pract
; 20(4-5): 111-122, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31533539
18.
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.
Infect Dis Ther
; 7(2): 183-195, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761330
19.
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
PLoS One
; 13(1): e0190487, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29304154
20.
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
HIV Clin Trials
; 19(4): 129-138, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30445896